'%20cy='5.2227'%20cx='-20.033'%20r='3.5391'%20fill='%23ffffff'/%3e%3c/g%3e%3cg%20opacity='.9'%3e%3ccircle%20fill-rule='evenodd'%20cx='-2.5033'%20transform='matrix(-.76604%20.64279%20.64279%20.76604%200%200)'%20cy='13.387'%20r='3.5391'%20stroke-width='0'%20fill='%23ffffff'/%3e%3c/g%3e%3cg%20opacity='.8'%3e%3ccircle%20stroke-width='0'%20fill-rule='evenodd'%20transform='matrix(-.17365%20.98481%20.98481%20.17365%200%200)'%20cy='8.3722'%20cx='16.173'%20r='3.5391'%20fill='%23ffffff'/%3e%3c/g%3e%3cg%20opacity='.7'%3e%3ccircle%20fill-rule='evenodd'%20cx='27.257'%20transform='matrix(.5%20.86603%20.86603%20-.5%200%200)'%20cy='-7.474'%20r='3.5391'%20stroke-width='0'%20fill='%23ffffff'/%3e%3c/g%3e%3cg%20opacity='.6'%3e%3ccircle%20stroke-width='0'%20fill-rule='evenodd'%20transform='matrix(.93969%20.34202%20.34202%20-.93969%200%200)'%20cy='-26.738'%20cx='25.562'%20r='3.5391'%20fill='%23ffffff'/%3e%3c/g%3e%3cg%20opacity='.5'%3e%3ccircle%20fill-rule='evenodd'%20cx='11.881'%20transform='matrix(.93969%20-.34202%20-.34202%20-.93969%200%200)'%20cy='-40.405'%20r='3.5391'%20stroke-width='0'%20fill='%23ffffff'/%3e%3c/g%3e%3cg%20opacity='.4'%3e%3ccircle%20stroke-width='0'%20fill-rule='evenodd'%20transform='matrix(.5%20-.86603%20-.86603%20-.5%200%200)'%20cy='-42.081'%20cx='-7.3838'%20r='3.5391'%20fill='%23ffffff'/%3e%3c/g%3e%3cg%20opacity='.3'%3e%3ccircle%20fill-rule='evenodd'%20cx='-23.219'%20transform='matrix(-.17365%20-.98481%20-.98481%20.17365%200%200)'%20cy='-30.981'%20r='3.5391'%20stroke-width='0'%20fill='%23ffffff'/%3e%3c/g%3e%3cg%20opacity='.2'%3e%3ccircle%20stroke-width='0'%20fill-rule='evenodd'%20transform='matrix(-.76604%20-.64279%20-.64279%20.76604%200%200)'%20cy='-12.299'%20cx='-28.215'%20r='3.5391'%20fill='%23ffffff'/%3e%3c/g%3e%3c/svg%3e){kind=small}
Home
Progress in Molecular Biology and Translational Science: Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B
Loading Inventory...
Barnes and Noble
Progress in Molecular Biology and Translational Science: Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B
Current price: $171.00
Barnes and Noble
Progress in Molecular Biology and Translational Science: Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B
Current price: $171.00
Loading Inventory...
Size: OS
*Product Information may vary - to confirm product availability, pricing, and additional information please contact Barnes and Noble
Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163
in the Progress in
Molecular Biology and Translational Science
series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for Modern Medicine, Low Molecular Weight Heparins and Their Clinical Applications, The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharid, Heparinoids as Clinically Used Drugs, Marine Glycan-Derived Therapeutics in China, Efficacy of Heparinoid PSS in Treating Cardiovascular and other Diseases—30 Years Clinical Applications in China, and more.
in the Progress in
Molecular Biology and Translational Science
series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for Modern Medicine, Low Molecular Weight Heparins and Their Clinical Applications, The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharid, Heparinoids as Clinically Used Drugs, Marine Glycan-Derived Therapeutics in China, Efficacy of Heparinoid PSS in Treating Cardiovascular and other Diseases—30 Years Clinical Applications in China, and more.
You May Also Like
More About Barnes and Noble at MarketFair Shoppes
Barnes & Noble does business -- big business -- by the book. As the #1 bookseller in the US, it operates about 720 Barnes & Noble superstores (selling books, music, movies, and gifts) throughout all 50 US states and Washington, DC. The stores are typically 10,000 to 60,000 sq. ft. and stock between 60,000 and 200,000 book titles. Many of its locations contain Starbucks cafes, as well as music departments that carry more than 30,000 titles.
Store Info
